Sclerostin: A candidate biomarker of SCI-induced osteoporosis

L. R. Morse; S. Sudhakar; A. A. Lazzari; C. Tun; E. Garshick; R. Zafonte; R. A. Battaglino

doi:10.1007/s00198-012-2072-0

Sclerostin: A candidate biomarker of SCI-induced osteoporosis

L. R. Morse, S. Sudhakar, A. A. Lazzari, C. Tun, E. Garshick, R. Zafonte, R. A. Battaglino

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker. Introduction: Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI. Methods: We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI. Results: After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002-0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18-0.99). Conclusion: These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.

Original language	English (US)
Pages (from-to)	961-968
Number of pages	8
Journal	Osteoporosis International
Volume	24
Issue number	3
DOIs	https://doi.org/10.1007/s00198-012-2072-0
State	Published - Mar 1 2013
Externally published	Yes

Bibliographical note

Funding Information:
This study received support from: the National Institute of Child Health and Human Development [R21HD057030 and R21HD057030-02S1], the National Institute of Arthritis and Musculoskeletal and Skin Diseases [1R01AR059270], and the Office of Research and Development, Rehabilitation Research and Development [Merit Review Grant B6618R].

Keywords

Bone biomarker
Osteoporosis
Rehabilitation medicine
Sclerostin
Spinal cord injury

Access

10.1007/s00198-012-2072-0

OpenUrl availability

Full text

Cite this

@article{b4f029a36c7646ec9f3cfa665826a90c,

title = "Sclerostin: A candidate biomarker of SCI-induced osteoporosis",

abstract = "We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker. Introduction: Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI. Methods: We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI. Results: After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002-0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18-0.99). Conclusion: These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.",

keywords = "Bone biomarker, Osteoporosis, Rehabilitation medicine, Sclerostin, Spinal cord injury",

author = "Morse, {L. R.} and S. Sudhakar and Lazzari, {A. A.} and C. Tun and E. Garshick and R. Zafonte and Battaglino, {R. A.}",

note = "Funding Information: This study received support from: the National Institute of Child Health and Human Development [R21HD057030 and R21HD057030-02S1], the National Institute of Arthritis and Musculoskeletal and Skin Diseases [1R01AR059270], and the Office of Research and Development, Rehabilitation Research and Development [Merit Review Grant B6618R]. ",

year = "2013",

month = mar,

day = "1",

doi = "10.1007/s00198-012-2072-0",

language = "English (US)",

volume = "24",

pages = "961--968",

journal = "Osteoporosis International",

issn = "0937-941X",

publisher = "Springer London",

number = "3",

}

TY - JOUR

T1 - Sclerostin

T2 - A candidate biomarker of SCI-induced osteoporosis

AU - Morse, L. R.

AU - Sudhakar, S.

AU - Lazzari, A. A.

AU - Tun, C.

AU - Garshick, E.

AU - Zafonte, R.

AU - Battaglino, R. A.

N1 - Funding Information: This study received support from: the National Institute of Child Health and Human Development [R21HD057030 and R21HD057030-02S1], the National Institute of Arthritis and Musculoskeletal and Skin Diseases [1R01AR059270], and the Office of Research and Development, Rehabilitation Research and Development [Merit Review Grant B6618R].

PY - 2013/3/1

Y1 - 2013/3/1

N2 - We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker. Introduction: Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI. Methods: We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI. Results: After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002-0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18-0.99). Conclusion: These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.

AB - We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker. Introduction: Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI. Methods: We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI. Results: After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002-0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18-0.99). Conclusion: These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.

KW - Bone biomarker

KW - Osteoporosis

KW - Rehabilitation medicine

KW - Sclerostin

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84878837676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878837676&partnerID=8YFLogxK

U2 - 10.1007/s00198-012-2072-0

DO - 10.1007/s00198-012-2072-0

M3 - Article

C2 - 22801952

AN - SCOPUS:84878837676

SN - 0937-941X

VL - 24

SP - 961

EP - 968

JO - Osteoporosis International

JF - Osteoporosis International

IS - 3

ER -

Sclerostin: A candidate biomarker of SCI-induced osteoporosis

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this